Aptose Biosciences Inc. (APTO)

1.83
NASDAQ
Prev Close 1.83
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.57 / 4.55
Exchange NASDAQ
Shares Outstanding 41.50B
Market Cap 75.94M
Div & Yield N.A. (N.A)

Latest News

Aptose To Present At The H.C. Wainwright Annual Global Life Sciences Conference

Aptose To Present At The H.C. Wainwright Annual Global Life Sciences Conference
Aptose Biosciences Establishes New At-the-Market Facility

Aptose Biosciences Establishes New At-the-Market Facility
Aptose Reports Results For The Fourth Quarter And Year Ended December 31, 2017

Aptose Reports Results For The Fourth Quarter And Year Ended December 31, 2017

Conference Call and Webcast at 5pm EDT Today

Aptose To Present New CG'806 And APTO-253 Data At The 2018 AACR Annual Meeting

Aptose To Present New CG'806 And APTO-253 Data At The 2018 AACR Annual Meeting

Aptose To Release Fourth Quarter And Year End December 31, 2017 Financial Results And Hold Conference Call On March 27, 2018

Aptose To Release Fourth Quarter And Year End December 31, 2017 Financial Results And Hold Conference Call On March 27, 2018

Aptose Biosciences Announces Exclusive License Agreement For Dual BET/Kinase Targeting Program With OHM Oncology

Aptose Biosciences Announces Exclusive License Agreement For Dual BET/Kinase Targeting Program With OHM Oncology

Aptose To Participate In Upcoming Investor Conferences In March 2018

Aptose To Participate In Upcoming Investor Conferences In March 2018

Aptose Biosciences Files New Preliminary Base Shelf Prospectus To Replace Expired Base Prospectus

Aptose Biosciences Files New Preliminary Base Shelf Prospectus To Replace Expired Base Prospectus

Aptose Biosciences To Present At Biotech Showcase™ 2018 Conference

Aptose Biosciences To Present At Biotech Showcase™ 2018 Conference

FDA Grants Orphan Drug Designation To Aptose Biosciences For CG'806 In Acute Myeloid Leukemia

FDA Grants Orphan Drug Designation To Aptose Biosciences For CG'806 In Acute Myeloid Leukemia

OHSU And Aptose Present CG'806 Preclinical Data At ASH 59th Annual Meeting

OHSU And Aptose Present CG'806 Preclinical Data At ASH 59th Annual Meeting

CG'806 reveals broad and potent single agent activity, and enhanced activity when combined with Bcl-2 or BET inhibitors, against AML and CLL patient samples

Aptose Presents New Preclinical Data On CG'806 Pan-FLT3/pan-BTK Inhibitor At ASH 59th Annual Meeting

Aptose Presents New Preclinical Data On CG'806 Pan-FLT3/pan-BTK Inhibitor At ASH 59th Annual Meeting

Data elucidate unique ability of CG'806 to kill a broad range of AML cells by suppressing multiple pathways, to overcome resistance caused by bone marrow stromal cells, and to act synergistically with other agents

Aptose Reports Results For The Third Quarter Ended September 30, 2017

Aptose Reports Results For The Third Quarter Ended September 30, 2017

Conference Call and Webcast at 5pm EST Today

Aptose To Release Third Quarter Ended September 30, 2017 Financial Results And Hold Conference Call On November 14, 2017

Aptose To Release Third Quarter Ended September 30, 2017 Financial Results And Hold Conference Call On November 14, 2017

Aptose To Present New CG'806 Data At The 2017 ASH Annual Meeting

Aptose To Present New CG'806 Data At The 2017 ASH Annual Meeting

Aptose Enters Into $15.5 Million Common Shares Purchase Agreement With Aspire Capital Fund, LLC

Aptose Enters Into $15.5 Million Common Shares Purchase Agreement With Aspire Capital Fund, LLC

Aptose Provides Corporate Update Highlights

Aptose To Present At The 17th Annual Biotech In Europe Forum

Aptose To Present At The 17th Annual Biotech In Europe Forum

Aptose Biosicences And CrystalGenomics Announce Issuance Of U.S. Patent For CG'806

Aptose Biosicences And CrystalGenomics Announce Issuance Of U.S. Patent For CG'806

Aptose Biosciences To Present At The 19th Annual Rodman & Renshaw Global Investment Conference

Aptose Biosciences To Present At The 19th Annual Rodman & Renshaw Global Investment Conference

Aptose Reports Results For The Second Quarter Ended June 30, 2017

Aptose Reports Results For The Second Quarter Ended June 30, 2017

Aptose Biosciences To Present At Canaccord Genuity 37th Annual Growth Conference

Aptose Biosciences To Present At Canaccord Genuity 37th Annual Growth Conference

Aptose To Release Second Quarter Ended June 30, 2017 Financial Results And Hold Conference Call On August 8, 2017

Aptose To Release Second Quarter Ended June 30, 2017 Financial Results And Hold Conference Call On August 8, 2017

Aptose Biosciences Announces Results Of Annual Meeting Of Shareholders

Aptose Reports Results For The First Quarter Ended March 31, 2017

Preclinical Data On Aptose Biosciences FLT3/BTK Inhibitor CG'806 Presented At AACR Hematologic Malignancies Meeting

Data support superiority of CG'806 relative to competitive agents against AML driven by diverse mutated forms of FLT3

OHSU And Aptose Present CG'806 Preclinical Data Demonstrating Potent Activity Against Patient Samples At AACR Hematologic Malignancies Meeting

Data support superiority of CG'806 relative to select competitive agents

Aptose Biosciences To Participate At The Bloom Burton & Co. Healthcare Investor Conference 2017

Aptose To Release First Quarter Ended March 31, 2017 Financial Results And Hold Conference Call On May 11, 2017

Provides Preliminary First Quarter 2017 Financial Information

Aptose Biosciences To Present CG'806 Data At AACR Hematologic Malignancies Meeting

Aptose Reports Fourth Quarter And Year End 2016 Results

Load More

From Our Partners

Aptose Biosciences (APTO) Presents At H.C. Wainwright & Co. Annual Global Life Sciences Conference - Slideshow
SeekingAlpha

FDA accepts Aptose's IND for CG-806; shares up 10% premarket
SeekingAlpha

Key events next week - healthcare (part 2)
SeekingAlpha

Aptose Biosciences beats by $0.02
SeekingAlpha

Aptose Biosciences nabs patent in Australia for CG-806
SeekingAlpha

Aptose Biosciences initiated with an Outperform at RBC Capital
The Fly

Aptose Biosciences initiated with an Outperform at RBC Capital
The Fly

Aptose Biosciences submits IND for CG-806; shares up 5% premarket
SeekingAlpha

WDC, APTO among premarket gainers
SeekingAlpha

Aptose Biosciences initiated with an Outperform at Oppenheimer
The Fly

Aptose Biosciences initiated with an Outperform at Oppenheimer
The Fly

Aptose Restarts Its Long Journey
SeekingAlpha

Investors returning to tiny biotechs
SeekingAlpha

Aptose Biosciences initiated with a Buy at B. Riley FBR
The Fly

Aptose Biosciences reports Q3 results
SeekingAlpha
Do You Understand
Your Portfolio?

TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.

Start Learning
Do You Know The 4 Pillars of Money Management?

TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.

Learn More
secure your
financial future

TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.

Start Learning
Get the Investing Edge.
Join Jim Cramer's Members-Only Investing Club
Become an Action Alerts PLUS member to learn from the pros how to invest wisely and build a customized portolio of blue chip stocks.
LEARN MORE
Uncover New Investment Opportunities With Our Team of Experts
Jim Cramer and his army of Wall Street pros serve up new trading ideas and in-depth market analysis every day.
LEARN MORE

Watchlist